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Outbreaks due to Clostridium difficile polymerase
chain reaction (PCR) ribotype 027, toxinotype III, were
detected in 7 hospitals in the Netherlands from April 2005
to February 2006. One hospital experienced at the same
time a second outbreak due to a toxin A–negative C. diffi-
cile PCR ribotype 017 toxinotype VIII strain. The outbreaks
are difficult to control. 
S
ince March 2003, outbreaks of severe cases of
Clostridium difficile–associated disease (CDAD) were
reported in hospitals in Montreal and Quebec (1,2).
Increased virulence was suspected, since the proportion of
patients with CDAD who died within 30 days after diagno-
sis rose from 4.7% in 1991–1992 to 13.8% in 2003 (1). In
addition, the Centers for Disease Control and Prevention
reported a growing threat of CDAD in US hospitals and
found the strain to be associated with high illness and
death rates during hospital outbreaks in 11 states (3). The
increased virulence was considered to be associated with
the production of a binary toxin and an increased produc-
tion of toxins A and B (4). Further characterization of this
strain showed that it belonged to toxinotype III, pulsed-
field gel electrophoresis (PFGE) type NAP1, restriction
endonuclease analysis group BI, and polymerase chain
reaction (PCR) ribotype 027 (2,3). Toxinotyping involves
detecting polymorphisms in the toxin A and B and sur-
rounding regulatory genes, an area of the genome known
collectively as the pathogenicity locus or PaLoc (5). By
toxinotyping, 24 different types can be recognized, where-
as the library of PCR ribotypes comprises 116 distinct
types of C. difficile identified on the basis of differences in
amplification profiles generated (6). The PCR ribotype
027, toxinotype III, strain is resistant to ciprofloxacin and
the newer generation of fluoroquinolones, such as gati-
floxacin, levofloxacin, and moxifloxacin (3). Exposure of
patients to fluoroquinolones and cephalosporins is recog-
nized as a risk factor for CDAD caused by 027 (2,3).
Increasing use of fluoroquinolones in US healthcare facil-
ities may have provided a selective advantage for this epi-
demic strain and promoted its widespread emergence.
The Outbreaks
In July 2005, the medical microbiologic laboratory at
the Leiden University Medical Center was requested to
type C. difficile strains from an outbreak in a hospital (hos-
pital l) in Harderwijk (Figure, Table). The incidence of
CDAD in the hospital had increased from 4 per 10,000
patient admissions in 2004 to 83 per 10,000 admissions
from April through July 2005. Cultured isolates were sub-
sequently identified as toxinotype III and PCR ribotype
027 (7). The strain also had the binary toxin genes and con-
tained an 18-bp deletion in a toxin regulator gene (tcdC).
As determined by E test (AB Biodisk, Solna Sweden), the
isolates were resistant to erythromycin (MIC >256 mg/L)
and ciprofloxacin (MIC >32 mg/L) and susceptible to clin-
damycin (MIC 2 mg/L) and metronidazole (MIC 0.19
mg/mL). Measures taken by the hospital included isolating
all patients with diarrhea until 2 tests were negative for C.
difficile toxin, cohorting all C. difficile–infected patients
on a separate ward, banning all fluoroquinolone use, and
limiting use of cephalosporins and clindamycin. A
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Figure. Location of the hospitals with outbreaks of Clostridium dif-
ficile–associated diarrhea in the Netherlands. The numbers corre-
spond with those in the Table. case-control study is being performed in the hospital to
determine risk factors for acquiring this strain, and a fol-
low-up study will determine the rate of complications and
relapses. As of January 2006, the situation appears to be
under control since the number of patients per month with
positive test results has decreased. All 9 CDAD cases from
September 2005 to January 2006 were caused by non-027
ribotypes. Therefore, cohort isolation and the limitation on
antimicrobial agents have been stopped. 
A second epidemic occurred in another hospital 30 km
from the first hospital (hospital 2, Amersfoort) and was
probably related to the outbreak in hospital 1 through a
transferred patient with CDAD. Isolates obtained from
patients were indistinguishable from the Harderwijk iso-
lates. After the index patient was transferred, the incidence
of CDAD, which had been 2–3 cases per month for the last
2 years, rose to an average of 15 cases per month during
May, June, and July. From August to December, the num-
ber of CDAD patients per month was 7, 7, 8, 14, and 10,
respectively. Of the 85 CDAD patients found through
December 2005, 19 (22%) patients died, and 16 (19%) had
relapses. Of 50 strains characterized at the reference labo-
ratory, 15 belonged to PCR ribotype 027, and 14 belonged
to PCR ribotype 017, toxinotype VIII. The 017 strain had
a deletion of the toxin A gene, did not contain genes for
binary toxin production, and had a normal tcdC gene.  
In response to the outbreaks in the Netherlands, the
Centre for Infectious Disease Control at the National
Institute for Public Health and the Environment in
Bilthoven organized a meeting with experts in the fields of
microbiology, infectious diseases, infection control, and
epidemiology. The team agreed to combine parts of exist-
ing national hospital guidelines relevant for infection con-
trol of CDAD and to use national and international
experience in drawing up specific CDAD guidelines for
infection control and treatment separate for hospitals and
nursing homes. Diagnostic facilities were increased and
made accessible for all microbiology laboratories in the
Netherlands. Relevant professionals were informed
through different communication channels, including vari-
ous scientific societies (7). Plans were made to register and
monitor new outbreaks. Laboratories were encouraged to
send patient isolates or fecal samples for typing to the ref-
erence laboratory in Leiden when an outbreak was suspect-
ed on the basis of an increase in monthly incidence or a
rapid spread of clinically suspected cases. 
Subsequently, 3 hospitals in the western part of the
country (hospitals 7–9) also reported an increase in inci-
dence of severe CDAD. In 2005, the public health labora-
tory serving these 3 hospitals diagnosed CDAD in 163
patients. Of 21 strains sent to the reference laboratory, 18
were identified as PCR ribotype 027, toxinotype III
(Table). Retrospectively, an increase of CDAD was first
evident in July 2004 for hospital 7 and in 2002 for hospi-
tal 9. The public health laboratory diagnosed CDAD in 120
patients in 2004, in 58 in 2003, and in 47 in 2002. No
strains or fecal samples before 2005 were available for typ-
ing. A nursing home in the same region was also found to
have patients with CDAD due to PCR ribotype 027, with
evidence of spread within the facility. No epidemiologic
relationship could be established between this region ad
that of the first 2 outbreaks.
Two hospitals in the center of the Netherlands (hospi-
tals 3 and 4) did not notice an increase in the incidence of
patients with CDAD but submitted strains to the reference
laboratory for typing. Type 027 was found in 6 (35%) of 17
and 1 (25%) of 4 isolates tested, respectively. None of the
patients with CDAD due to type 027 had severe disease.
A cluster of 12 patients with CDAD by PCR ribotype
027, toxinotype III, was reported in July and August in a
large teaching hospital in Amsterdam (hospital 5). One
patient died from consequences of CDAD, and severe
complications developed in 2 other patients. Another hos-
pital in Amsterdam (hospital 6) also reported an increase of
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Strains cultured from fecal samples of 7 patients in August
2005 showed PCR ribotype 027, toxinotype III. 
Conclusions
Shortly after the reports in June 2005 of the detection of
C. difficile PCR ribotype 027, toxinotype III, in English
hospitals, this more virulent type was detected in the
Netherlands (7,8). More recently, the reference laboratory
at Leiden University Medical Center also detected this
strain in samples from Belgium as a causative agent of out-
breaks of CDAD (9). The virulence factors of this emerg-
ing strain are not well understood. It contains a binary
toxin, but the importance of binary toxin as a virulence
factor in C. difficile has not been established. The binary
toxin, an actin-specific adenosine diphosphate–ribosyl-
transferase, is encoded by the cdtA gene (the enzymatic
component) and the cdtB gene (the binding component),
which are not located within the pathogenicity locus
(10,11). Nonpathogenic strains that contain cdtA and cdtB
genes but lack the pathogenicity locus are also capable of
producing binary toxin. The binary toxin is present in ≈6%
of all C. difficile isolates, irrespective of the toxinotype
(10,11). We therefore consider it likely that the binary
toxin in PCR ribotype 027, toxinotype III, strains merely
reflects clonal spread of a restricted number of strains. 
The importance of the 18-bp deletion in tcdC of the
PCR ribotype 027, toxinotype III, strains is also unknown.
tcdC is considered a negative regulator of the production
of toxins A and B, but whether this 18-bp deletion results
in a nonfunctional product is unknown (3). Arecent report,
however, indicates that toxinotype III isolates produce tox-
ins A and B in considerably greater quantities in vitro than
toxinotype 0 isolates (4). On the other hand, deletions in
tcdC are frequently present in toxinogenic isolates. Of 32
toxinogenic strains studied in 2002, 8 belonged to toxino-
types 0, V, and VI and contained deletions in tcdC of 18 bp
or 39 bp, although this deletion was not associated with
severity of disease (12). 
The PCR ribotype 027, toxinotype III, strain has a
characteristic antimicrobial susceptibility pattern, since it
is resistant to the newer fluoroquinolones and erythromy-
cin but susceptible to clindamycin. Macrolide, lin-
cosamide, and streptogramin B (MLSB) resistance is
usually due to an erm(B) gene, but PCR ribotype 027 and
toxinotype III strain did not contain an erm(B) gene. All
current PCR ribotype 027 and toxinotype III strains but no
historical isolates (obtained before 2001) were resistant to
gatifloxacin and moxifloxacin (3). The resistance for
ciprofloxacin and newer fluoroquinolones is not specific
for the new virulent strains, since it has also been found in
other common PCR ribotypes in the United Kingdom
(13). 
The observation that outbreaks due to different strains
can occur simultaneously emphasizes that microbiologic
monitoring is important for epidemiologic studies of
CDAD. PCR ribotype 017 strain lacks a part of the toxin A
gene and was first recognized as a cause of an outbreak in
Canada in 1999 (14). Subsequently, toxin A–negative,
toxin B–positive strains caused outbreaks of CDAD in
Ireland (D. Drudy, pers. comm.), Argentina (M.C. Legaria,
et al., unpub. data), and the Netherlands (15). 
The outbreaks in the Netherlands are difficult to con-
trol. In the Harderwijk epidemic, using rapid diagnostic
tests for CDAD and cohort isolation in combination with
restricting use of fluoroquinolones and cephalosporins
appeared to be successful. Outbreaks in the other hospitals
are still not completely under control.
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